Abstract
LAG-3, through interaction with a variety of ligands, regulates T cell function via inhibition of T cell proliferation and activation. It has been demonstrated to be overexpressed on tumor infiltrating lymphocytes (TILs) of a variety of cancers with associated poor outcomes. The purpose of this study is to characterize the expression pattern and clinical significance of LAG-3 in pediatric Hodgkin lymphoma (HL). Patient tumor samples from Children’s Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed for the expression of LAG-3 and PD-L1 using immunohistochemistry. 73/115 patients (63%) demonstrated positive LAG-3 staining. No demographic or survival outcome data were significantly associated with LAG-3 expression. Interestingly, patients with the lowest density of expression were found to have the worst EFS, and those with highest density of expression demonstrated the best EFS. There was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression. This project is innovative in its characterization of LAG-3 as an immune checkpoint target in pediatric HL.
Original language | English (US) |
---|---|
Pages (from-to) | 606-613 |
Number of pages | 8 |
Journal | Leukemia and Lymphoma |
Volume | 62 |
Issue number | 3 |
DOIs | |
State | Published - 2021 |
Keywords
- LAG-3
- Pediatric Hodgkin lymphoma
- immune checkpoint
- immunotherapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research